{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:56:19Z","timestamp":1791122179081,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":1445,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.jhep.2009.04.003","type":"journal-article","created":{"date-parts":[[2009,4,18]],"date-time":"2009-04-18T08:49:52Z","timestamp":1240044592000},"page":"403-410","source":"Crossref","is-referenced-by-count":110,"title":["Antiviral therapy of chronic hepatitis B: Opportunities and challenges in Asia"],"prefix":"10.1016","volume":"51","author":[{"given":"Yun-Fan","family":"Liaw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2009.04.003_bib1","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","article-title":"Hepatitis B virus infection","volume":"373","author":"Liaw","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2009.04.003_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2893.2003.00487.x","article-title":"Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures","volume":"11","author":"Lavanchy","year":"2004","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2009.04.003_bib3","unstructured":"The World Bank. GNI 2007 Atlas Method. World development indicators database 2008 September. Available from: http:\/\/www.worldbank.org\/."},{"key":"10.1016\/j.jhep.2009.04.003_bib4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1440-1746.2004.03420.x","article-title":"Practical difficulties in the management of hepatitis B in the Asia-Pacific region","volume":"19","author":"Mohamed","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2009.04.003_bib5","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1111\/j.1478-3231.2006.01370.x","article-title":"Hepatitis B: overview of the burden of disease in the Asia-Pacific region","volume":"26","author":"Lesmana","year":"2006","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2009.04.003_bib6","first-page":"1","article-title":"Centers for Disease Control and Prevention (CDC). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection","volume":"57","author":"Weinbaum","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jhep.2009.04.003_bib7","first-page":"133","article-title":"Epidemiology and natural history of hepatitis B in Vietnam","volume":"2","author":"Ryan","year":"2008","journal-title":"Curr Hep B Rep"},{"key":"10.1016\/j.jhep.2009.04.003_bib8","first-page":"137","article-title":"HBV prevalence, natural history, and treatment in Eastern Europe, Turkey, and Turkish-Speaking Countries in Central Asia","volume":"2","author":"Yurdaydin","year":"2008","journal-title":"Curr Hep B Rep"},{"key":"10.1016\/j.jhep.2009.04.003_bib9","first-page":"159","article-title":"Epidemiology, presentation, and treatment of chronic HBV infection in Mainland China, in Taiwan, and in Chinese Americans in the United States","volume":"2","author":"Pan","year":"2008","journal-title":"Curr Hep B Rep"},{"key":"10.1016\/j.jhep.2009.04.003_bib10","first-page":"166","article-title":"HBV prevalence, natural history, and treatment in Korea and the United States","volume":"2","author":"Han","year":"2008","journal-title":"Curr Hep B Rep"},{"key":"10.1016\/j.jhep.2009.04.003_bib11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s12072-007-9033-2","article-title":"Role of viral factors in the natural course and therapy of chronic hepatitis B","volume":"1","author":"Kao","year":"2007","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2009.04.003_bib12","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1001\/jama.1987.03390190075023","article-title":"A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers","volume":"257","author":"Chen","year":"1987","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2009.04.003_bib13","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2007.02.055","article-title":"Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies","volume":"132","author":"Ni","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2009.04.003_bib14","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0929-6646(09)60231-X","article-title":"Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants","volume":"106","author":"Chen","year":"2007","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jhep.2009.04.003_bib15","first-page":"123","article-title":"Natural history differences in perinatally versus adult-acquired disease","volume":"3","author":"Chu","year":"2004","journal-title":"Curr Hepatitis Rep"},{"key":"10.1016\/j.jhep.2009.04.003_bib16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1046\/j.1440-1746.2003.02976.x","article-title":"Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy","volume":"18","author":"Liaw","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2009.04.003_bib17","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","article-title":"Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B","volume":"35","author":"Hsu","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.04.003_bib18","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjmed.2003.12.040","article-title":"Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels","volume":"116","author":"Chu","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2009.04.003_bib19","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/hep.1840130403","article-title":"Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study","volume":"13","author":"Liaw","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.04.003_bib20","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/hep.20240","article-title":"HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects","volume":"39","author":"Yuen","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.04.003_bib21","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/hep.21612","article-title":"HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up","volume":"45","author":"Chu","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.04.003_bib22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12072-007-5001-0","article-title":"Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study","volume":"1","author":"Chen","year":"2007","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2009.04.003_bib23","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1053\/gast.2002.36026","article-title":"Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection","volume":"123","author":"Chen","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2009.04.003_bib24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12072-007-9002-9","article-title":"Spontaneous relapse of hepatitis in inactive HBsAg carrier","volume":"1","author":"Chu","year":"2007","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2009.04.003_bib25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jhep.2005.03.018","volume":"43","author":"Chu","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2009.04.003_bib26","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1365-2893.2007.00957.x","article-title":"Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection","volume":"15","author":"Papatheodoridis","year":"2008","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2009.04.003_bib27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/hep.21724","article-title":"Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase","volume":"46","author":"Hui","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.04.003_bib28","doi-asserted-by":"crossref","unstructured":"Tai DI, Lin SM, Sheen IS, Chu CM, Lin DT, Liaw YF. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 2009. doi:10.1002\/hep.22878.","DOI":"10.1002\/hep.22878"},{"key":"10.1016\/j.jhep.2009.04.003_bib29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/hep.1840080310","article-title":"The development of cirrhosis in patients with chronic type B hepatitis: a prospective study","volume":"8","author":"Liaw","year":"1988","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.04.003_bib30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2006.08.021","article-title":"Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma","volume":"46","author":"Lin","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2009.04.003_bib31","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1055\/s-2006-939752","article-title":"Hepatitis B virus-related cirrhosis: natural history and treatment","volume":"26","author":"Chu","year":"2006","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2009.04.003_bib32","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors","volume":"48","author":"Fattovich","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2009.04.003_bib33","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa013215","article-title":"Hepatitis B e antigen and the risk of hepatocellular carcinoma","volume":"347","author":"Yang","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2009.04.003_bib34","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Risk Evaluation of Viral Load Elevation and Associated Liver Disease\/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2009.04.003_bib35","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2009.04.003_bib36","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1177\/135965350601100614","article-title":"Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy","volume":"11","author":"Liaw","year":"2006","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2009.04.003_bib37","unstructured":"IMS Health Taiwan. Taiwan hepatitis B disease awareness and attitude in general population 2005. [File of Bristol-Myers Squibb]."},{"key":"10.1016\/j.jhep.2009.04.003_bib38","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/hep.21784","article-title":"Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California","volume":"46","author":"Lin","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.04.003_bib39","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1572-0241.2007.01060.x","article-title":"Hepatitis B virus infection in 6,130 unvaccinated Korean-Americans surveyed between 1988 and 1990","volume":"102","author":"Hann","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2009.04.003_bib40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJM199807093390201","article-title":"A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group","volume":"339","author":"Lai","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2009.04.003_bib41","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa021812","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B","volume":"348","author":"Hadziyannis","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2009.04.003_bib42","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2009.04.003_bib43","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone and the two in combination in patients with HBeAg negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2009.04.003_bib44","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2009.04.003_bib45","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa051285","article-title":"A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B","volume":"354","author":"Chang","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2009.04.003_bib46","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa051287","article-title":"Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B","volume":"354","author":"Lai","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2009.04.003_bib47","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1053\/j.gastro.2006.04.007","article-title":"Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B","volume":"130","author":"Sherman","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2009.04.003_bib48","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1056\/NEJMoa066422","article-title":"Telbivudine versus lamivudine in patients with chronic hepatitis B","volume":"357","author":"Lai","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2009.04.003_bib49","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2009.04.003_bib50","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/hep.510300313","article-title":"Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B","volume":"30","author":"Chien","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.04.003_bib51","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.510300221","article-title":"Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy","volume":"30","author":"Liaw","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.04.003_bib52","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1053\/jhep.2000.16665","article-title":"Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea","volume":"32","author":"Song","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.04.003_bib53","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0168-8278(02)00419-1","article-title":"The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B","volume":"38","author":"Chien","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2009.04.003_bib54","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2009.04.003_bib55","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1053\/jhep.2001.25084","article-title":"Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy","volume":"33","author":"Leung","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.04.003_bib56","first-page":"706A","article-title":"Long-term entecavir therapy results in reversal of fibrosis\/cirrhosis and continued histologic improvement in patients with HBeAg(+) and (\u2212) chronic hepatitis B: results from studies ETV-022, -027 and -901","volume":"48","author":"Liaw","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.04.003_bib57","doi-asserted-by":"crossref","unstructured":"Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. Core Working Party for Asia-Pacific Consensus on Hepatitis B and C. J Gastroenterol Hepatol 2000;15:825\u201341.","DOI":"10.1046\/j.1440-1746.2000.02324.x"},{"key":"10.1016\/j.jhep.2009.04.003_bib58","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update","volume":"2","author":"Liaw","year":"2008","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2009.04.003_bib59","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1097\/00004836-200411003-00004","article-title":"A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore","volume":"38","author":"Li","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2009.04.003_bib60","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1097\/00004836-200411003-00005","article-title":"Cost of chronic hepatitis B infection in the United States","volume":"38","author":"Lee","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2009.04.003_bib61","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1097\/00004836-200411003-00006","article-title":"Cost of chronic hepatitis B virus infection in Taiwan","volume":"38","author":"Hsieh","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2009.04.003_bib62","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1097\/00004836-200411003-00007","article-title":"Cost of chronic hepatitis B infection in South Korea","volume":"38","author":"Yang","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2009.04.003_bib63","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1097\/00004836-200411003-00009","article-title":"Hepatitis B management costs in France, Italy, Spain, and the United Kingdom","volume":"38","author":"Brown","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2009.04.003_bib64","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1097\/00004836-200411003-00010","article-title":"Cost of chronic hepatitis B infection in China","volume":"38","author":"Zhiqiang","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2009.04.003_bib65","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1097\/00004836-200411003-00012","article-title":"The direct cost of managing patients with chronic hepatitis B infection in Australia","volume":"38","author":"Butler","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2009.04.003_bib66","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s12072-008-9049-2","article-title":"The economics of treating chronic hepatitis B in Asia","volume":"2","author":"Dan","year":"2008","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2009.04.003_bib67","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.21627","article-title":"Management of hepatitis B: summary of a clinical research workshop","volume":"45","author":"Hoofnagle","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2009.04.003_bib68","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.bpg.2008.11.003","article-title":"Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success","volume":"22","author":"Chien","year":"2008","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2009.04.003_bib69","first-page":"333","article-title":"What barriers do primary care physicians face in the management of patients with chronic hepatitis B infection in primary care?","volume":"46","author":"Tan","year":"2005","journal-title":"Singapore Med J"},{"key":"10.1016\/j.jhep.2009.04.003_bib70","series-title":"Asia-Pacific pocket guide to hepatitis B","year":"2006"},{"key":"10.1016\/j.jhep.2009.04.003_bib71","first-page":"51","article-title":"Advancing the clinical treatment of hepatitis B virus in the Asian-Pacific region","volume":"26","author":"Liaw","year":"2006","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2009.04.003_bib72","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/S0168-8278(03)00269-1","article-title":"Impact of hepatitis B immunization, Europe and worldwide","volume":"39","author":"Namgyal","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2009.04.003_bib73","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1016\/j.vaccine.2008.09.056","article-title":"The global impact of vaccination against hepatitis B: a historical overview","volume":"26","author":"Zanetti","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2009.04.003_bib74","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.cgh.2007.05.004","article-title":"Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B","volume":"5","author":"Keeffe","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2009.04.003_bib75","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/135965350901400107","article-title":"On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future","volume":"14","author":"Liaw","year":"2009","journal-title":"Antivir Ther"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827809002426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827809002426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T18:37:10Z","timestamp":1710268630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827809002426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0168827809002426"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2009.04.003","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}